Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Prevenar Approval Expected By End of February

Executive Summary

Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.
Advertisement

Related Content

Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole
Wyeth Protonix I.V. Indicated As Second-Line Therapy After Oral Pantoprazole
EMEA Clears Four Biologics In 1999 Before FDA, And Five Later Than FDA
P&G Merger Talks May Herald Next Step In Consumer-Focused Rx Marketing
AHP Redux Litigation Roster Adds Fraud Suit From Interneuron
Wyeth-Ayerst Low-Dose Premarin Filings Slated For 2000
Wyeth-Ayerst's Protonix
Wyeth To Seek Prevenar Otitis Media Indication In Future Submission
Wyeth To Seek Prevenar Otitis Media Indication In Future Submission
AHP Enbrel Market Expansion Plans Include Up To 2.4 Mil. U.S. Patients
Advertisement
UsernamePublicRestriction

Register

PS035540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel